FDA 483 - Grifols Diagnostic Solutions Inc. - December 13, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Grifols Diagnostic Solutions Inc. in Emeryville, CA, a licensed antigen component manufacturer for IVDs, revealed significant deficiencies in process validation. The firm failed to appropriately validate the manufacturing process for licensed antigen HCV c100-3, opting for an inadequate verification approach. Additionally, the firm did not conduct required trend analyses of process data across all antigen types to ensure manufacturing processes are in a qualified state.
ID · 51b3d794-1098-4918-9288-0b6b272d627a